# PAOLA-1 / ENGOT-ov25

Source: https://onco.cc/trials/paola-1/  
OnCo record `paola-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding olaparib to bevacizumab maintenance roughly doubled progression-free time in tumours with faulty DNA repair, and improved survival in that group.

## Summary

PFS 22.1 vs 16.6 months overall (HR 0.59) and 37.2 vs 17.7 months in HRD-positive tumours (HR 0.33; NEJM 2019). Five-year OS in HRD-positive patients was 65.5% vs 48.4% (HR 0.62; Annals of Oncology 2023). No benefit in HRD-negative disease. Approved in 2020 for HRD-positive tumours; it established HRD testing as a decision point.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT02477644
- Phase: 3
- Setting: Newly diagnosed advanced ovarian cancer already on bevacizumab maintenance: adding olaparib vs placebo
- Sponsor: ARCAGY-GINECO / AstraZeneca
- Enrolled: 806
- Result: PFS HR 0.59 overall, 0.33 HRD-positive; 5-year OS 65.5% vs 48.4% in HRD-positive.
- Outcomes: Progression-free survival (HRD-positive): Olaparib + bevacizumab 37.2 months vs Placebo + bevacizumab 17.7 months, HR 0.33; Overall survival at 5 years (HRD-positive): Olaparib + bevacizumab 65.5% vs Placebo + bevacizumab 48.4%, HR 0.62

## Sources

- ClinicalTrials.gov NCT02477644: https://clinicaltrials.gov/study/NCT02477644
- NEJM 2019: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361

## Connected records

- cancers: [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/)
- technologies: [HRD genomic scar scores (GIS, LOH, HRDetect)](https://onco.cc/technologies/hrd-genomic-scar-scores/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [myChoice CDx](https://onco.cc/drugs/mychoice-cdx/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/)
- terms: [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/)
- people: [Isabelle Ray-Coquard](https://onco.cc/people/isabelle-ray-coquard/)
- pairings: [PARP inhibitor + bevacizumab maintenance (HRD-positive)](https://onco.cc/pairings/parp-plus-bevacizumab/)
- institutions: [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/)

---
JSON: https://onco.cc/api/v1/entities/paola-1.json